| Ytd | -84.50% | |
| 1y | -84.25% |
| Open | 4.63 | Prev Close | 4.62 | Low | 4.20 | High | 5.16 | Mkt Cap | 204.53M |
| Vol | 69.81K | Avg Vol | 146.84K | EPS | 0.15 | P/E | 31.07 | Forward P/E | N/A |
| Beta | 5.31 | Short Ratio | 1.79 | Inst. Own | 4.90% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-28 | 50-d Avg | 7.34 | 200-d Avg | 19.75 | 1yr Est | 0.00 |
Gainers Anbio Biotechnology (NASDAQ:NNNN) stock moved upwards by 16.9% to $6.49 during Friday's
JOYY Inc (NASDAQ: JOYY) reported Q2 earnings below estimates, but beat revenue expectations. Shares
H World Group (HTHT) beats earnings and raises sales guidance, shares jump 8.1%. Other big gainers i
Gainers INVO Fertility (NASDAQ:IVF) shares increased by 163.4% to $2.56 during Monday's pre-mar
Health care sector oversold - buying opportunities in undervalued companies. RSI compares stock stre
Oversold health care stocks: EVMN, NNNN, NAUT. RSI <30 shows they may be undervalued. EVMN drop
Health care sector's oversold stocks present buying opportunity; RSI below 30 signals oversold,
Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) and Oncocyte (NASDAQ: IMDX - Get Free Report) a
Oncocyte (NASDAQ: IMDX - Get Free Report) and Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) a
Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) and Oncocyte (NASDAQ: IMDX - Get Free Report) a
Oncocyte (NASDAQ: IMDX - Get Free Report) and Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) a
Oncocyte (NASDAQ: IMDX - Get Free Report) and Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) a
Oncocyte (NASDAQ: IMDX - Get Free Report) and Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) a
Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) and Oncocyte (NASDAQ: IMDX - Get Free Report) a
Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) and Oncocyte (NASDAQ: IMDX - Get Free Report) a
Oncocyte (NASDAQ: IMDX - Get Free Report) and Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) a
Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) and Oncocyte (NASDAQ: IMDX - Get Free Report) a
Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) and Oncocyte (NASDAQ: IMDX - Get Free Report) a
Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) and Oncocyte (NASDAQ: IMDX - Get Free Report) a
Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) and Oncocyte (NASDAQ: IMDX - Get Free Report) a
Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) and Oncocyte (NASDAQ: IMDX - Get Free Report) a
Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) and Oncocyte (NASDAQ: IMDX - Get Free Report) a
Oncocyte (NASDAQ: IMDX - Get Free Report) and Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) a
Oncocyte (NASDAQ: IMDX - Get Free Report) and Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) a
Oncocyte (NASDAQ: IMDX - Get Free Report) and Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) a
Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) and Oncocyte (NASDAQ: IMDX - Get Free Report) a
Oncocyte (NASDAQ: IMDX - Get Free Report) and Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) a
Trump's second term is fueling an IPO comeback, with 2025 listings up 50% and five stocks alread